去甲长春花碱为主的方案治疗晚期非小细胞肺癌的临床观察

目的 观察去甲长春花碱(NVB)与顺铂(DDP)两药联合组成NP方案及去甲长春花碱、顺铂和异环磷酰胺(IFO)三药联合组成NIP方案治疗晚期非小细胞肺癌的疗效和毒性。方法 48例晚期非小细胞肺癌随机分为NP和NIP两组。结果 NIP组有效率为54.1％,NP组有效率为45.9％,两组差异无显著性(P>0.05)。两组剂量限制性毒性为骨髓抑制,白细胞下降发生率为100％,Ⅲ～Ⅳ度骨髓抑制在NIP组为70.8％,NP组为62.5％,两组问差异无显著性(P>0.05)。消化道反应可耐受。结论 NP和NIP方案是治疗晚期非小细胞肺癌疗效高、可耐受的理想方案,三药联合较二药联合疗效高,虽反应较重,但可以耐受。

Clinical observation on treatment of advanced non-small cell lung cancer with the regimen containing mainly navelbine

Objective To evaluate the efficacy and toxicity of NIP(NVB + IFO + DDP)regimen and NP (DDP+ NVB)regimen in treatment of non-small cell lung cancer(NSCLC). Methods Forty-eight cases of advanced NSCLC were randomly divided into NIP regimen group and NP regimen group. Results The results showed that the response rates of NIP group and NP group were 54.1% and 45.9% respectively, with no statistically significant difference between them( P > 0.05) .The dose-limiting toxicity was neutropenia which was seen in all treated cases and 70.8% and 62.5% were grade III and grade IV inhibition in NIP group and NP group respectively. Gastric irritation was tolerable. Conclusion Both of these two regimens are effective and tolerable in the treatment of advanced NSCLC.The regimen of NVB,DDP plus IFO is better than NVB plus DDP. Although the former causes more severe toxic reaction, it can be tolerable.